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http://dx.doi.org/10.1016/j.jaci.2015.11.020Methods: One hundred ninety-four asthmatic patients and 21
control subjects recruited from 2 separate centers underwent
detailed clinical assessment, sputum induction, and phlebotomy.
One hundred three clinical, physiologic, and inflammatory
parameters were analyzed by using topological data analysis
and Bayesian network analysis.
Results: Severe asthma was associated with anxiety and
depression, obesity, sinonasal symptoms, decreased quality of
life, and inflammatory changes, including increased sputum
chitinase 3–like protein 1 (YKL-40) and matrix
metalloproteinase (MMP) 1, 3, 8, and 12 levels. Topological data
analysis identified 6 clinicopathobiologic clusters replicated in
both geographic cohorts: young, mild paucigranulocytic; older,
sinonasal disease; obese, high MMP levels; steroid resistant TH2
mediated, eosinophilic; mixed granulocytic with severe
obstruction; and neutrophilic, low periostin levels, severe
obstruction. Sputum IL-5 levels were increased in patients with
severe particularly eosinophilic forms, whereas IL-13 was
suppressed and IL-17 levels did not differ between clusters.
Bayesian network analysis separated clinical features from
intricately connected inflammatory pathways. YKL-40 levels
strongly correlated with neutrophilic asthma and levels of
myeloperoxidase, IL-8, IL-6, and IL-6 soluble receptor. MMP1,
MMP3, MMP8, and MMP12 levels were associated with severe
asthma and were correlated positively with sputum IL-5 levels
but negatively with IL-13 levels.
Conclusion: In 2 distinct cohorts we have identified and
replicated 6 clinicopathobiologic clusters based on blood and
induced sputum measures. Our data underline a disconnect
between clinical features and underlying inflammation, suggest
IL-5 production is relatively steroid insensitive, and highlight
the expression of YKL-40 in patients with neutrophilic
inflammation and the expression of MMPs in patients with
severe asthma. (J Allergy Clin Immunol 2016;138:61-75.)
Key words: Asthma, cytokines, eosinophils, neutrophils, phenotype,
endotype, heterogeneity, matrix metalloproteinase, chitinase 3–like
protein 1, topological data analysis
Asthma is a chronic inflammatory disorder of the airways
characterized by variable airflow obstruction and airway remod-
eling and mediated by a variety of inflammatory mediators and
cells, including mast cells, T cells, eosinophils, and neutrophils.161
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62 HINKS ET ALAbbreviations usedACQ: Asthma Control QuestionnaireECP: Eosinophil cationic proteinFENO: Fraction of exhaled nitric oxideFGF: Fibroblast growth factorGINA: Global Initiative for AsthmaHAD: Hospital Anxiety and DepressionICS: Inhaled corticosteroidK-S: Kolmogorov-SmirnovMMP: Matrix metalloproteinaseTDA: Topological data analysisYKL-40: Chitinase 3–like protein 1There is now recognition of considerable disease heterogeneity
within the spectrum of clinical asthma, the precise nature of
which remains to be defined, and this currently constitutes a
significant barrier to research.2 It is postulated that distinct
subgroups of asthma exist, which have been termed endotypes,
meaning ‘‘a subtype of a condition defined by distinct pathophys-
iological mechanisms.’’3 A better understanding of such
endotypes and their relationship to distinct underlying disease
mechanisms should enable identification of novel therapeutic tar-
gets and facilitate the aim of stratified medicine (ie, the efficient
targeting of specific therapies to subgroups of subjects likely to
benefit most).
To date, several groups have reported cluster analyses of patient
cohorts to investigate possible disease endotypes.4-9 However,
these are often limited by a lack of robust statistical validation
in replication cohorts or have generated clusters the identity of
which is dominated by predominantly clinical parameters, such
as pulmonary physiology or participants’ demographics, without
providing significant insight into the underlying pathophysiology.
Furthermore, techniques like principle component analysis tend
to accentuate separation between clusters, which might in reality
represent groupings within a continuum of disease rather than
clear-cut entities.9 Recently, we have piloted a new analytic
approach to such large clinical data sets by using network ana-
lyses that allow truly multidimensional analysis of clusters and
provide visual representations of the data that reveal continuities
within data sets.10
The aim of this study was to identify and independently
replicate distinct multidimensional clinicopathobiologic clusters
of severe asthma from the participants in the Wessex Severe
Asthma cohort who had induced sputum and peripheral blood
biomarker measures, as well as detailed clinical characterization.
We aimed to cluster participants using only parameters that could
be available to a clinician in tertiary care with access to sputum
induction facilities and then to investigate the disease mecha-
nisms of airway inflammation in each of these clusters by using
more advanced immunologic assays.METHODS
Southampton participants (derivation cohort)
The derivation cohort comprised 213 adult participants (18-70 years)
enrolled for clinical phenotyping in the Wessex Severe Asthma Cohort, at
the NIHR Southampton Respiratory Biomedical Research Unit. Five were
excluded because of alternative diagnoses of bronchiectasis (n 5 3),
interstitial lung disease (n 5 1), and gastroesophageal reflux without
asthma. One hundred forty-five participants underwent successful sputuminduction, with the emphasis on severe asthma (n 5 121) and inclusion of
8 healthy nonatopic participants, 9 patients with mild asthma receiving
b2-agonists alone, and 7 patients with moderate asthma receiving inhaled
corticosteroids (ICSs). Thirty-eight of the 121 patients with severe
asthma with persistent symptoms despite high-dose ICSs and other
therapy were also receiving daily oral corticosteroids (Table I and see
the Methods section and Fig E1 in this article’s Online Repository at
www.jacionline.org).Portsmouth participants (validation cohort)
The validation cohort comprised 108 adult participants (18-70 years)
enrolled by a separate study team from outpatient clinics at Queen Alexandra
Hospital, Portsmouth. Seventy-one participants underwent successful sputum
induction: 13 healthy nonatopic participants, 1 patient with mild asthma,
6 patients with moderate asthma, and 50 patients with severe asthma with
persistent symptoms despite high-dose ICSs (n5 32) and oral corticosteroids
(n 5 18, Table II and see Fig E1).Study procedures
Participants were assessed based on history; examination; questionnaires,
including the AsthmaControl Questionnaire (ACQ),11 AsthmaQuality of Life
Questionnaire,12 Hospital Anxiety and Depression (HAD) Scale,13
Sino-Nasal Outcome Test 20,14 and Short-Form 36 Health Survey15; skin
prick tests with common aeroallergens; spirometry with albuterol
reversibility; exhaled nitric oxide measurements; the University of
Pennsylvania smell identification test16; and serum IgE and urinary cotinine
measurements. Sputum samples were obtained by means of hypertonic saline
induction and processed as previously described.17 Fifty-five different
inflammatory mediators were measured in serum and sputum by using
ELISAs or cytokine bead arrays (see the Methods section in this article’s
Online Repository).
The study was approved by the Southampton and South West Hampshire
Research Ethics Committee A (09/H0502/37). All participants provided
informed consent.Statistical analysis
Data were analyzed initially by using topological data analysis (TDA) to
define multidimensional clusters in the derivation and validation cohorts
separately. Standard statistical methods were then applied to define the
features of these clusters. In a separate analysis to define relationships between
these parameters, Bayesian network analysis was then applied to all the
pathobiologic and clinical features on the highest quality data from both
cohorts combined.
Data are expressed as medians with interquartile ranges, unless stated
otherwise. Data were logarithmically transformed if they were not normally
distributed. For all analyses, 2-tailed P values of less than .05 were considered
significant. Data were compared between the healthy and control groups by
using Mann-Whitney U or Student t tests and between each asthma severity
group and control subjects by using the Kruskal-Wallis test or ANOVA,
depending on data distribution. For the latter, an overall 5% significance level
was adjusted for multiple comparisons by using the Bonferroni method.
Correlations were tested with the Spearman r statistic. Kolmogorov-
Smirnov (K-S) tests identified significant differences between distributions
within a single cluster. Data were analyzed with Prism 6.0 (GraphPad
Software, San Diego, Calif) and SPSS 21.0 (IBM, Armonk, NY) software.
Network analyses (TDA and Bayesian network analysis) were performed,
as previously described.10 Networks were generated from all participants with
the most complete data (n5 145 for the derivation data set and n5 70 for the
validation data set) after missing data (6.1%of data set) were imputed by using
the mean of 5 multiple imputations. Subsequent analyses of sputum
parameters used only data from the highest quality sputum samples
(n 5 118 for the derivation data set and n 5 55 for the validation data set)
and without imputation. Terms used to generate the networks are described
in Tables E1 and E2 in this article’s Online Repository at www.jacionline.org.
TABLE I. Demographics of clusters in the derivation cohort
Parameters
Healthy
control
subjects
Cluster
A B C D E F G H
No.* 8 30 7 13 4 13 17 37 19
Demographics
Sex (male/female),
no. (%)
3 (38)/5 (72) 9 (30)/21 (70) 4 (57)/3 (43) 3 (23)/10 (77) 2 (50)/2 (50) 6 (46)/7 (54) 9 (53)/8 (47) 13 (35)/24 (65) 9 (47)/10 (53)
Age (y), median
(range)
33.5 (21-53) 38 (22-65) 60 (39-67) 44 (21-57) 54.5 (23-61) 45 (26-62) 57 (29-68) 51 (23-69) 58 (43-71)
Pulmonary function
FEV1 (% predicted,
pre-BD)
89 (84-98) 91 (83-105) 58 (53-64) 80 (72-94) 99 (63-115) 64 (58-83) 40 (31-64) 74 (55-84) 44 (35-59)
FEV1 reversibility (%) 0 (0.0-1.8) 6.8 (4.1-9.3) 16 (5.7-23) 5.8 (2.6-11) 4.7 (0.68-11) 8.7 (2.7-20) 12 (8.2-24) 11 (3.3-20) 14 (3.3-25)
FEV1 (% predicted,
post-BD)
92 (84-98) 96 (87-112) 67 (63-76) 85 (70-104) 112 (71-122) 75 (64-87) 52 (30-77) 82 (66-88) 54 (44-66)
Exhaled nitric oxide
(ppb, at 50 L/s)
13 (11-17) 26 (12-52) 25 (19-45) 11 (9.5-19) 20 (16-35) 33 (11-73) 22 (17-46) 19 (10-29) 17 (10-30)
Clinical
Atopy (positive skin
test response,
yes/no), no. (%)
4 (50)/4 (50) 22 (73)/8 (27) 4 (57)/3 (43) 5 (38)/8 (62) 3 (75)/1 (25) 11 (82)/2 (18) 12 (71)/5 (29) 22 (59)/15 (41) 13 (68)/6 (32)
No. of allergens
eliciting positive
skin test responses
1 (0-23) 3 (0-5) 3 (0-4) 0 (0-4) 2 (1-4) 2 (1-5) 3 (0-6) 2 (0-4) 2 (0-3)
Peripheral eosinophil
count (109/L)
0.1 (0.1-0.3) 0.2 (0.1-0.4) 0.2 (0.1-0.4) 0.3 (0.1-0.6) 0.2 (0.1-1.3) 0.6 (0.4-0.7) 0.4 (0.1-0.7) 0.2 (0.1-0.2) 0.2 (0.1-0.3)
Total IgE (IU/mL) 230 (79-280) 120 (30-260) 88 (23-210) 34 (11-110) 130 (37-190) 68 (13-812) 380 (110-1400) 92 (12-260) 130 (28-290)
Body mass index
(kg/m2)
23.5
(22.4-25.6)
31.3
(26.7-35.7)
28.0
(27.6-35.5)
36.4 (32.4-41.7) 34.6
(25.6-37.9)
25.9 (23.3-29.0) 28 (25.8-37.2) 25.5
(24.3-29.8)
30.9
(28.6-36.5)
Smoking status
Never, no. (%) 5 (72) 15 (50) 5 (71) 4 (31) 4 (100) 7 (54) 10 (59) 17 (46) 10 (53)
Former, no.
(% [mean
pack years])
3 (38 [3.3]) 12 (40 [14]) 2 (29 [29]) 7 (54 [16]) 0 (0) 6 (46 [3]) 6 (35 [22]) 14 (38 [16]) 5 (26 [13])
Current, no.
(% [mean
pack years])
0 (0) 3 (10 [13]) 0 (0) 2 (15 [23]) 0 (0) 0 (0) 1 (5.9 [6.5]) 6 (16 [28]) 4 (21 [35])
Duration of
asthma (y)
NA 19 (5-31) 30 (15-49) 21 (6-32) 12 (9.3-20) 29 (21-42) 34 (25-47) 29 (18-44) 43 (23-47)
ACQ7 score NA 1.6 (0.9-2.7) 2.3 (1.7-4.1) 2.7 (2.1-3.7) 2.1 (0.43-2.7) 2.9 (1.7-4.0) 3.1 (2.3-3.9) 3.3 (2.4-3.9) 3.3 (2.5-4.2)
Treatment
Inhaled steroid dose
(equivalent mg
of BDP)
0 1240 (0-2160) 2400
(1600-2400)
1440
(1220-2080)
1640
(400-1860)
1600
(800-1840)
2000
(1760-2000)
1640
(1280-2080)
1600
(920-2300)
Maintenance oral
corticosteroids
(yes/no), no. (%)
0 (0)/8 (0) 5 (17)/25 (83) 0 (0)/7 (100) 5 (38)/8 (62) 2 (50)/2 (50) 6 (46)/7 (54) 5 (29)/12 (71) 12 (32)/25 (68) 3 (16)/16 (84)
Inflammatory subtype, no. (%)
Neutrophilic 0 (0) 0 (0) 3 (43) 3 (23) 0 (0) 0 (0) 6 (35) 8 (22) 13 (68)
Eosinophilic 1 (13) 6 (20) 3 (43) 3 (23) 2 (50) 0 (0) 4 (24) 10 (27) 1 (5)
Mixed granulocytic 0 (0) 0 (0) 1 (14) 1 (8) 0 (0) 9 (69) 4 (24) 3 (8) 2 (10)
Paucigranulocytic 7 (87) 24 (80) 0 (0) 6 (46) 2 (50) 4 (31) 3 (18) 16 (43) 3 (16)
Sputum cell differential (%)
Macrophages 70 (58-85) 70 (57-76) 17 (7.7-28) 44 (28-59) 64 (26-68) 41 (25-51) 13 (5.3-48) 36 (26-55) 25 (9.7-29)
Neutrophils 12 (7.7-30) 19 (13-28) 66 (57-84) 52 (40-61) 21 (22-27) 30 (22-41) 65 (47-91) 53 (34-64) 71 (64-88)
Eosinophils 0.75 (0.60-1.3) 1.3 (0.0-2.6) 5.3 (0.3-13) 0.25 (0.0-1.3) 2 (0.13-17) 14 (1.8-43) 2.8 (1.2-8.1) 1 (0.3-6.0) 0.75 (0.06-1.38)
Lymphocytes 0.0 (0.0-0.0) 0.0
(0.0-0.38)
0.0 (0.0-0.0) 0.0 (0.0-0.25) 0.0 (0.0-0.06) 0.0 (0.0-0.25) 0 (0.0-0.31) 0.15 (0.0-0.30) 0.0 (0.0-0.19)
Epithelial 2.4 (1.5-11) 8.0 (2.5-12) 1.3 (0.9-7.0) 4.0 (1.0-6.0) 9.1 (0.38-14) 3.4 (2.2-4.9) 1.3 (0.25-2.4) 2.8 (1.5-9.8) 1.2 (0.31-3.7)
The inflammatory subtype is based on sputum differentials by using the following cut points: neutrophilic, greater than 61%; eosinophilic, greater than 3%. Percentages shown are
derived from those subjects with valid data.
ACQ, Asthma Control Questionnaire11; BD, bronchodilator; BDP, beclomethasone dipropionate; CT, computed tomography; FVC, forced vital capacity; GINA, Global Initiative for
Asthma; NA, not available; PEFR, peak expiratory flow rate.
*Because some subjects were outliers, not all are assigned to clusters A through H.
Values are medians with interquartile ranges, unless stated otherwise.
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TABLE II. Demographics of clusters in the validation cohort
Parameters
Healthy
control
subjects
Cluster
a b c e f h i
No.* 13 4 9 7 5 19 9 5
Demographics
Sex (male/female),
no. (%)
5 (8)/8 (62) 3 (75)/1 (25) 7 (78)/2 (22) 3 (43)/4 (57) 1 (20)/4 (80) 12 (63)/7 (37) 2 (22)/7 (72) 3 (60)/2 (40)
Age (y), median (range) 34 (18-53) 34 (23-51) 61 (29-79) 44 (30-62) 61 (45-71) 51 (29-79) 57 (30-73) 45 (41-50)
Pulmonary function
FEV1 (% predicted,
pre-BD)
104 (96-108) 103 (95-109) 57 (52-62) 73 (68-78) 50 (49-52) 60 (51-78) 48 (44-69) 75 (75-85)
FEV1 reversibility (%) 0 (0.0-0.0) 2.1 (20.3-4.7) 8.4 (1.2-17) 11 (5.3-13) 5.8 (2.6-17) 13.3 (5.7-15) 7.5 (6.2-14) 9.3 (5.0-9.4)
FEV1 (% predicted,
post BD)
104 (96-108) 105 (97-111) 61 (53-73) 78 (73-86) 53 (51-62) 70 (58-83) 53 (50-73) 81 (80-87)
Exhaled nitric oxide
(ppb, at 50 L/s)
14 (11-18) 39 (28-72) 32 (17-68) 26 (17-53) 72 (17-98) 32 (18-64) 27 (16-52) 28 (14-51)
Clinical
Atopy (positive skin
test response, yes/no),
no. (%)
4 (31)/9 (69) 3 (75)/1 (25) 8 (89)/1 (11) 6 (83)/1 (17) 4 (80)/1 (20) 13 (68)/6 (32) 5 (56)/44 (44) 4 (80)/1 (20)
No. of allergen eliciting
positive skin test
responses
0 (0-0) 3.5 (2-6) 3 (1-4) 2 (2-4) 2 (1-3) 3 (0-4.5) 1 (0-4) 5 (5-5)
Peripheral eosinophil
count (109/L)
0.1 (0.1-0.1) 0.1 (0.1-0.2) 0.5 (0.3-0.5) 0.3 (0.1-0.4) 0.2 (0.1-0.3) 0.5 (0.2-0.9) 0.3 (0.0-0.4) 0.5 (0.5-0.6)
Total IgE (IU/mL) 21 (8.8-52) 77 (34-130) 116 (69-136) 145 (79-1500) 149 (100-860) 130 (54-170) 73 (32-540) 266 (140-400)
Body mass index (kg/m2) 24.3 (21.9-28.4) 29.4 (26.1-31.5) 26.4 (25.9-29.0) 30.9 (27.8-33.5) 27.3 (26.4-28.4) 29.1 (26.4-32.1) 26.2 (41.0-29.1) 32.1 (27.2-34.2)
Smoking status
Never, no. (%) 11 (85) 1 (25) 2 (22) 4 (57) 2 (40) 10 (53) 6 (67) 2 (60)
Former, no.
(% [mean pack years])
2 (15 [2.5]) 3 (75 [6]) 7 (78 [25]) 3 (43 [19]) 2 (40% [25]) 8 (42 [20]) 3 (33 [17]) 3 (40% [16])
Current, no.
(% [mean pack years])
0 (0) 0 (0) 0 (0) 0 (0) 1 (20 [32]) 1 (5.3 [32]) 0 (0) 0 (0)
Duration of asthma (y) NA 16 (12-22) 26 (14-38) 30 (19-47) 13 (5-16) 33 (18-46) 22 (6-41) 41 (21-41)
ACQ7 score NA 0.76 (0.43-1.2) 3.4 (2.9-4.0) 2.3 (1.9-3.2) 3.6 (3.0-4.1) 2.9 (2.4-3.6) 3.4 (2.7-4.0) 3.1 (3.0-3.3)
Treatment
Inhaled steroid dose
(equivalent mg of BDP)
0 3280 (2280-3940) 1600 (1600-2000) 2880 (1840-4440) 2000 (2000-2880) 1600 (1600-2000) 2240 (1270-2850) 2000 (2000-2000)
Maintenance oral
corticosteroids
(yes/no), no. (%)
0 (0)/13 (100) 0 (0)/4 (100) 4 (44)/5 (56) 2 (29)/5 (71) 2 (40)/3 (60) 6 (32)/13 (68) 3 (33)/6 (66) 3 (60)/2 (40)
Inflammatory subtype, no. (%)
Neutrophilic 0 (0) 0 (0) 1 (11) 2 (29) 0 (0) 6 (32) 3 (33) 0 (0)
Eosinophilic 0 (0) 0 (0) 5 (56) 2 (29) 3 (60) 9 (47) 2 (22) 2 (40)
Mixed granulocytic 0 (0) 0 (0) 1 (11) 0 (0) 0 (0) 1 (5) 3 (33) 0 (0)
Paucigranulocytic 13 (100) 4 (100) 2 (22) 3 (43) 2 (40) 3 (16) 1 (11) 3 (60)
Sputum cell differential (%)
Macrophages 82 (69-89) 70 (63-78) 26 (19-54) 34 (25-39) 52 (12-67) 30 (22-51) 24 (17-31) 84 (75-89)
Neutrophils 18 (11-33) 26 (17-34) 50 (42-50) 45 (39-53) 18 (9.9-23) 50 (32-70) 67 (51-76) 16 (3.8-17)
Eosinophils 0.0 (0.0-0.2) 0.0 (0.0-0.13) 11 (3.8-25) 0.69 (0.38-30) 42 (5.4-79) 4.9 (2.0-13) 7.4 (1.8-19) 3.3 (0.29-6.7)
Lymphocytes 0.2 (0.0-0.63) 0.1 (0.05-0.68) 0.94 (0.5-1.2) 0.69 (0.25-1.5) 0.25 (0.0-0.53) 0.63 (0.5-1.3) 1.4 (1.0-1.6) 0.38 (0.19-0.50)
Epithelial 0.1 (0.0-0.3) 1.0 (1.0-1.5) 0.5 (0.22-1.0) 0.69 (0.16-0.94) 0.69 (0.0-2.1) 1.8 (0.38-2.0) 0.5 (0.25-0.76) 0.19 (0.10-1.6)
The inflammatory subtype is based on sputum differentials by using the following cut points: neutrophilic, greater than 61%; eosinophilic, greater than 3%. Percentages given are
derived from those subjects with valid data.
ACQ, Asthma Control Questionnaire11; BD, bronchodilator; BDP, beclomethasone dipropionate; CT, computed tomography; FVC, forced vital capacity; GINA, Global Initiative for
Asthma; NA, not available; PEFR, peak expiratory flow rate.
*Because some subjects were outliers, not all are assigned to clusters a through i.
Values are medians with interquartile ranges, unless stated otherwise.
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To identify multidimensional features within the data sets, whichmight not
be apparent by using traditional methods, we used TDA. This is particularly
suited to complex biological data sets, representing a high-dimensional data
set as a structured 3-dimensional network. Each node comprises participants
similar to each other inmultiple dimensions. Edges connect nodes that contain
shared data points. Statistical tests can then be performed on groups or features
that emerge from the inherent structure of the data set. This technique provides
a geometric representation of the data,18,19 is independent of prior hypotheses,and detects multidimensional features within the data that become apparent on
visualization. As a consequence, topological networks capture interesting
structure, even in very small data sets.
TDAwas performed, as previously described,10,19 by usingAyasdi Core 1.59
(Ayasdi,MenloPark,Calif), constructing networkswith the 29parameters listed
in Table E1. Variance-normalized Euclidean distance was used as a distance
metric with 2 filter functions: principal and secondary metric singular value
decomposition. Resolution was set at 30 and gain at 3 (derivation) or 4 (valida-
tion) and selected to provide network structures that permitted identification of
J ALLERGY CLIN IMMUNOL
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the rest of the structure. Comparisons between multiple clusters used 1-way
ANOVA, with post hoc tests with the Bonferroni correction.Bayesian network analysis
Interconnectivity between clinical and pathobiologic parameters was
explored by using Bayesian network analysis (Genie 2.0; Decision Systems
Laboratory, University of Pittsburgh, Pittsburgh, Pa). Data were discretized to
describe nonlinear correlations into 2 (binary variables) or 4 or 5 (continuous
variables) bins. Seventy-four parameters were included in analyses (see
Table E2) on the 173 participants (including 17 healthy control subjects) from
both cohorts with the highest quality sputum data and without imputation. The
strengths of associations found to be significant in this analysis were analyzed
by using Spearman correlations.RESULTS
First, we investigated which of the 103 clinical, physiologic,
and pathobiologic parameters measured were associated with
severe asthma (Global Initiative for Asthma [GINA] step 4 and 5).
Features that differed significantly in K-S tests between patients
with severe asthma and healthy subjects in both the derivation
data set (n5 145 participants) and the validation data set (n5 70)
are presented in Table III. The presence of severe asthma was
associated with symptoms of anxiety and depression or nasal
dysfunction, decreased quality-of-life scores, obesity, obstructive
spirometry, and increased reversibility. Pathobiologic parameters
associated with a diagnosis of severe asthma were neutrophilic
sputum; an increase in peripheral blood neutrophil counts; serum
and sputum chitinase 3–like protein 1 (YKL-40) levels; sputum
matrix metalloproteinase (MMP) 1, MMP3, MMP8, and
MMP12 levels (P < .0001 each, Fig 1); vascular endothelial
growth factor, IL-5, IL-6, IL-8, and IL-6 soluble receptor levels;
and a decrease in sputum macrophage counts and levels of tissue
inhibitor of metalloproteinases 1, fibroblast growth factor, IL-1
receptor antagonist, and IL-2.TDA to identify clusters
Next, we applied TDA to the Southampton cohort (derivation)
data sets to identify multidimensional clinicopathobiologic
clusters. The network was generated by using only 29 clinical,
physiologic, and cellular parameters (see Table E1) with the
potential to be available to a tertiary care clinician. Subsequent
cluster analyses were then performed on data available from all
103 parameters. Eight clusters of asthmatic patients (A-H) were
identified, as described in Tables I and IV and Fig 2. Of these, 6
clusters (A-C, E, F, and H) were subsequently replicated when
the same analysis was applied to the geographically distinct
Portsmouth (validation) cohort (Tables II and IV and see Figs
E2-E4 in this article’s Online Repository at www.jacionline.
org), which also identified a small additional cluster (cluster i)
not present in the Southampton cohort. Healthy control subjects
formed distinct clusters in both analyses.
Of the 6 clusters replicated in both data sets, cluster
A (young, mild, paucigranulocytic) comprises participants
with predominantly paucigranulocytic sputum, few symptoms
(the lowest ACQ7 scores, 0.8-1.6), and low serum periostin
levels who are young (lowest median ages, 34-38 years) and
more likely to be at GINA treatment step 2 (low-dosemaintenance
ICS).Subjects in cluster B (older, sinonasal disease) have the highest
median age, more symptoms of anxiety and depression (highest
median HAD score, 12-27), more nasal symptoms (highest
Sino-Nasal Outcome Test 20 score), and high levels of serum
periostin and sputum MMP3.
Subjects in cluster C (obese, high MMP levels) have the highest
body mass index (30.9-36.4 kg/m2); increased sputum MMP1,
MMP2, andMMP8 concentrations; and low serum periostin levels.
Subjects in cluster E (steroid-resistant TH2-mediated, eosino-
philic) have high serum periostin levels, sputum eosinophilia,
sputum IL-5 levels, and fraction of exhaled nitric oxide (FENO)
levels despite high-dose ICSs (1600-2000 mg of beclomethasone
dipropionate) or oral corticosteroids (40% to 46% of
participants).
Subjects in cluster F (mixed granulocytic inflammation
with severe obstruction) have both sputum eosinophilia and
neutrophilia with lower prebronchodilator FEV1 values and
FEV1/forced vital capacity ratios associated with higher sputum
periostin and eosinophil cationic protein (ECP) levels and high
HAD scores.
Subjects in cluster H (neutrophilic disease with severe
obstruction and low periostin levels) have high sputum neutrophil
counts with fixed airflow obstruction (low prebronchodilator and
postbronchodilator FEV1) associated with very high symptom
scores (median ACQ7, 3.3-3.4) and low serum periostin levels.
Of the clusters that were not replicated in both data sets, both
clusters D and i were small (n 5 4 and 5, respectively) and
therefore might represent model overfitting. Lastly, cluster G
shared many features with cluster H, comprising a second large
cluster of participants with blood and sputum neutrophilia, high
symptom scores, and low serum periostin levels. When clusters G
and H were compared directly, cluster G had higher prebroncho-
dilator and postbronchodilator FEV1, higher sputum macrophage
counts, and higher serum periostin levels and were less neutro-
philic, with lower sputum neutrophil counts and sputum
myeloperoxidase (MPO), MMP8, and MMP9 levels (data not
shown). Thus clusters G and H could be considered to represent
milder and more severe subgroups, respectively, of neutrophilic
asthma with low periostin levels.
Features of specific interest were compared across these TDA
clusters. Serum periostin levels were significantly lower in
clusters C and H in both the training and validation cohorts (see
Fig E4). Although sputum IL-5 concentrations were significantly
increased in severe clusters B through H, sputum IL-13 concen-
trations were significantly decreased in most of the severe clusters
B, C, F, and H (see Fig E4). By contrast, no significant differences
were observed in sputum IL-17 concentrations between healthy
subjects and subjects of any cluster (data not shown).
A qualitative comparison of these clusters and clusters we have
previously identified by using similar methodology in a small and
distinct cohort, the IL-17 cohort,10 is presented in Table E3 and
Fig E5 in this article’s Online Repository at www.jacionline.
org. Clusters A, E, F, and H showed clear similarities to analogous
clusters in the IL-17 cohort, although clusters B and C did not.Bayesian network analysis of combined data sets
Next, to investigate the interactions between the diverse
clinical, physiologic, and pathobiologic parameters in the data
sets, we applied Bayesian network analysis to 74 nonredundant
parameters in data from 173 participants from both cohorts with
TABLE III. Clinical and pathologic features found to be associated with patients with severe asthma compared with healthy subjects
Derivation data set
Feature Healthy subjects Patients with severe asthma
K-S tests
K-S score P value
No.* 8 121
Increased in asthmatic patients compared with healthy subjects
Reversibility (%) 0.0 (0.0-1.8) 10 (2.9-21) 0.590 .01
BMI 23.5 (22.4-25.6) 31.2 (26.7-37.3) 0.566 .02
HAD score 4.0 (1.8-7.8) 15 (10-22) 0.597 .01
HAD Depression score 1 (1-3) 9 (6-11) 0.680 .01
Nasal dysfunction 0.35 (0.09-0.39) 0.48 (0.42-0.72) 0.558 .02
SNOT-20 12 (1.5-27) 35 (24-48) 0.507 .04
Serum YKL-40 (ng/mL) 17 (13-22) 83 (55-140) 0.787 <.001
Blood neutrophil count (109/L) 3.9 (3.2-4.5) 6.1 (4.3-8.4) 0.603 .008
Sputum neutrophil count (%) 12 (7.7-30) 51 (28-68) 0.571 .01
Sputum MMP3§ 3.7 3 1024 (3.7 3 1024-3.9 3 1024) 2.6 3 1022 (1.3 3 1022-5.9 3 1022) 0.931 <.001
Sputum MMP12§ 7.0 3 1025 (6.3 3 1026-1.4 3 1024) 1.0 3 1022 (5.9 3 1023-1.6 3 1022) 0.774 .002
Sputum MMP8§ 0.12 (0.049-0.21) 9.6 (2.2-27) 0.628 .02
Sputum MMP1§ 1.6 3 1024 (3.3 3 1025-3.6 3 1024) 1.1 3 1022 (6.2 3 1023-2.1 3 1022) 0.627 .02
Sputum VEGF 230 (220-280) 700 (470-1100) 0.814 .001
Sputum IL-6 soluble receptor (pg/mL) 41 (8.0-99) 260 (140-430) 0.607 .03
Sputum IL-6 (pg/mL) 0.0 (0.0-0.0) 50 (17-120) 0.873 <.001
Sputum IL-5 (pg/mL) 0.0 (0.0-0.0) 0.76 (0.18-6.4) 0.627 .02
Sputum IL-8 (pg/mL) 190 (100-420) 3300 (1000-8200) 0.676 .01
Sputum YKL-40 (ng/mL) 3.2 (2.5-8.7) 65 (20-150) 0.647 .02
Decreased in asthmatic patients compared with healthy subjects
FEV1/FVC ratio 80 (77-83) 66 (54-72) 0.752 <.001
FEV1 (% predicted, pre-BD) 89 (84-98) 68 (49-84) 0.560 .008
FEV1 (% predicted, post-BD) 92 (84-98) 78 (58-90) 0.608 .02
AQLQ score 7 (7-7) 3.7 (3.0-4.8) 0.936 <.001
SF-36 89 (71-91) 42 (27-61) 0.776 <.001
Sputum macrophage count (%) 70 (58-85) 36 (23-56) 0.646 .001
Sputum TIMP-1 (ng/mL) 1.7 3 105 (7.2 3 104-2.5 3 106) 1.2 3 104 (5.2 3 103-3.8 3 104) 0.725 .005
Sputum IL-2 (pg/mL) 1.8 (0.27-2.7) 0.0 (0.0-0.0) 0.627 .02
Sputum IL-1RA (pg/mL) 2.6 3 104 (2.4 3 104-2.8 3 104) 2.7 3 103 (0.0-1.2 3 104) 0.941 <.001
Sputum FGF (pg/mL) 53 (43-62) 0.0 (0.0-0.60) 0.941 <.001
These features were found to differ significantly between healthy subjects and patients with severe asthma (British Thoracic Society steps 4 and 5) in both training and validation
data sets.
AQLQ, Juniper Asthma Quality of Life Questionnaire; BD, bronchodilator; BDP, beclomethasone dipropionate equivalent; BMI, body mass index; FGF, fibroblast growth factor;
FVC, forced vital capacity; GINA, Global Initiative for Asthma; IL-1RA, IL-1 receptor antagonist; MPO, myeloperoxidase; SF-36, Short-Form 36 Health Survey; SNOT-20,
Sino-Nasal Outcome Test 20; TIMP-1, tissue inhibitor of metalloproteinases 1; VEGF, vascular endothelial growth factor.
*Values are medians with interquartile ranges, unless stated otherwise.
Statistical tests were performed on transformed data.
‘‘Nasal dysfunction’’ is a composite average score on a scale of 0 to 1 derived from SNOT-20 scores, hyposmia, and rhinosinusitis.
§MMPs are expressed as a ratio to tissue inhibitor of metalloproteinases values; statistical tests were performed on transformed data.
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66 HINKS ET ALthe highest quality sputum data (Fig 3). This Bayesian network
provides a graphic representation of the probabilistic depen-
dencies among the parameters and arises from the data by using
machine learning inferred from the joint probability distributions
of the data. In the figure the breadth of each line represents the
strength of the interaction (Euclidean distance). Forty-one of
the parameters were included in the model by the analysis,
whereas 33 parameters without strong interactions were
excluded from the model, including sex, FENO values, revers-
ibility, peripheral blood counts, and serum periostin levels (see
Table E2). Within the network, strong associations were observed
between clinical parameters, and separately, strong associations
were observed between pathobiologic parameters. However, aprominent feature of the network is a lack of associations between
pathobiologic parameters and clinical parameters, with the
exceptions of fibroblast growth factor, which is strongly
negatively correlated with GINA treatment step, and atopic status,
which is positively associated with sputum IL-2 levels.
Sputum YKL-40 levels are highly connected within the
network, particularly with levels of sputum MPO (Spearman
rs 5 0.884, P < .0001), IL-8 (rs 5 0.837, P < .0001), and sputum
IL-6 soluble receptor (rs 5 0.758, P < .0001; Fig 4, A, B, and E).
Sputum YKL-40 levels correlated moderately with sputum
neutrophil counts (rs 5 0.484, P < .0001; Fig 4, G) and were
increased more in patients with neutrophilic versus eosinophilic
disease (see Fig E6, A, in this article’s Online Repository at
Validation data set
Healthy subjects Patients with severe asthma
K-S tests
K-S score P value
13 50
0.0 (0.0-0.0) 8.8 (3.3-14) 0.841 <.001
24.3 (21.9-28.4) 29.0 (26.0-32.2) 0.452 .03
3.0 (0.0-5.0) 16 (9.0-25) 0.637 <.001
2 (0-2) 8.5 (5.3-12) 0.734 <.001
0.0 (0.0-0.43) 0.39 (0.13-0.53) 0.708 <.001
0.0 (0.0-3.0) 37 (20-53) 0.739 <.001
27 (19-37) 110 (67-160) 0.739 <.001
2.9 (2.7-4.0) 5.6 (4.4-8.5) 0.545 .004
18 (11-33) 45 (29-67) 0.732 <.001
1.6 3 1024 (9.9 3 1025-2.3 3 1024) 3.2 3 1022 (1.5 3 1022-5.9 3 1022) 0.902 <.001
3.7 3 1025 (1.2 3 1025-5.5 3 1025) 1.0 3 1022 (5.1 3 1023-1.9 3 1022) 0.878 <.001
0.04 (0.030-0.077) 21 (5.4-28) 0.854 <.001
5.7 3 1025 (3.6 3 1025-1.5 3 1024) 1.2 3 1022 (6.7 3 1023-2.0 3 1022) 0.732 <.001
580 (520-710) 1000 (620-1300) 0.519 .02
130 (100-215) 480 (260-840) 0.623 .002
10 (2.3-19) 55 (15-170) 0.567 .007
0.0 (0.0-0.080) 3.1 (0.72-9.8) 0.714 <.001
620 (380-880) 4000 (2100-7100) 0.756 <.001
21 (14-31) 150 (48-270) 0.738 <.001
85 (84-88) 66 (58-74) 0.785 <.001
100 (96-108) 60 (49-75) 0.918 <.001
100 (96-110) 68 (52-81) 0.857 <.001
7.0 (7.0-7.0) 4.1 (3.1-4.9) 0.959 <.001
89 (85-92) 46 (33-65) 0.841 <.001
82 (69-89) 30 (19-52) 0.837 <.001
4.7 3 105 (2.3 3 105-1.5 3 106) 1.7 3 104 (6.3 3 103-3.8 3 104) 0.860 <.001
0.95 (0.0-3.1) 0.0 (0.0-0.0) 0.612 .003
2.6 3 104 (2.2 3 104-3.5 3 104) 1.4 3 104 (1.1 3 104-1.8 3 104) 0.745 <.001
48 (44-57) 1.2 (2.5 3 1023-1.2) 0.860 <.001
TABLE III. (Continued)
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HINKS ET AL 67www.jacionline.org). Sputum YKL-40 levels negatively
correlated with lung function, particularly postbronchodilator
FEV1 (rs 5 20.270, P 5 .0004, data not shown). Sputum and
serum YKL-40 values are only moderately correlated
(rs5 0.434, P <.0001; Fig 4, H), which has implications for their
utility as a serum biomarker.
Levels of sputum MPO and sputum elastase, markers of
neutrophilic airways inflammation, are highly connected within
the network (Fig 3 and see Fig E7 in this article’s Online
Repository at www.jacionline.org).MMP12 levels are also highly
connected, being positively associated with MMP1, MMP3,
MMP8, and MMP13 levels (Fig 3 and see Fig E8 in this article’sOnline Repository at www.jacionline.org). Because MMP8
can induce the decoy receptor IL-13 receptor a2,20 a negative
association between MMP concentrations and free IL-13 might
be expected. Indeed, concentrations of these MMPs correlate
negatively with sputum IL-13 levels (rs 5 20.371 to 20.452,
see Fig E9 in this article’s Online Repository at www.
jacionline.org) but positively with sputum IL-5 levels
(rs5 0.481 to 0.559,P <.0001; see Fig E10 in this article’s Online
Repository at www.jacionline.org). MMP/tissue inhibitor of
metalloproteinases 1 ratios are also associated with body mass
index, particularly MMP1, MMP3, and MMP12 (rs 5 0.373,
0.303, and 0.311, respectively; P < .0001 each; data not shown).
FIG 1. Protease/antiprotease balance in asthmatic patients. MMP/tissue inhibitor of metalloproteinases
(TIMP-1) ratios in sputum in asthmatic patients compared with healthy subjects for MMP1 (A), MMP3 (B),
MMP8 (C), and MMP12 (D) are shown. Horizontal lines show medians. Statistical comparisons were done
with Student t tests on log-transformed data.
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68 HINKS ET ALAlthough sputum IL-5 levels are strongly associated with
sputum eosinophilia (rs 5 0.572, P < .0001) and sputum ECP
levels (rs 5 0.604, P < .0001, see Figs E6 and E11 in this
article’s Online Repository at www.jacionline.org), sputum
IL-13 levels are not highly correlated with sputum IL-5
levels (P 5 .6) and, conversely, are suppressed in both patients
with neutrophilic and those with eosinophilic asthma (see
Fig E6, D), suggesting that IL-13 production, which is strongly
associated with GINA treatment step, is more steroid
responsive than IL-5. These differences between associations of
sputum ECP, IL-5, and IL-13 levels are further explored in
Figs E11-E15 in this article’s Online Repository at
www.jacionline.org, which reveal that IL-5 is associated with a
wider range of inflammatory markers than IL-13, including
makers of neutrophilic inflammation (IL-8 and YKL-40). Thus
disparities between IL-5 and IL-13 can have additional causes:
given the association of IL-5 with ECP, which can be produced
by both neutrophils and eosinophils,21 and that the eosinophil
activation product major basic protein can increase eosinophil
IL-8 production,22 the biology is complex, and IL-5 seems to
have a broader effect than IL-13.
Fig E16 in this article’sOnlineRepository atwww.jacionline.org
presents 12 key sputum parameters stratified according to GINA
treatment group. For each of these parameters, no significant
differences were observed between distributions for GINA step 4
compared with step 5 (receiving an additional median 10 mg/d
oral prednisone), which would argue against our main observations
being attributable wholly to therapeutic corticosteroids.DISCUSSION
We have previously demonstrated the potential utility of
topological and Bayesian analytic techniques to analyze high-
dimensional flow cytometric data from a bronchoscopy study in a
small asthma cohort in which we identified distinct multidimen-
sional clinicopathologic clusters.10 Here we apply the same
analytic approach to 2 much larger severe asthma cohorts,
clustering patients by using only real-world assays already
accessible to clinicians in tertiary referral centers for severe
asthma. This provides endotypes that both relate to the underlying
biology and are clinically meaningful.
In addition to the large study size and the statistically unbiased
approach, a major strength of this study is the use of 2
geographically distinct cohorts. This provides true external
validation of the derivation cohort model in contrast to
studies that simply use a random split of a single data set, which
provides only a weak and inefficient form of internal validation.23
The focus of our analyses is on differences within the
spectrum of asthma. Although the number of healthy control
subjects included is only modest, this has little effect on the
identity of these endotypes, which are defined by comparison
with all other subjects in the study. Although a larger
sample size would enable a more detailed description of the
clusters, the sensitivity of TDA to detect structure in small data
sets and the external validation provide statistical confidence in
the features described. A further strength of this study is the
breadth of additional data on serum and airway inflammatory
mediators also available for analysis, providing new insights
TABLE IV. Definitions of clusters in the derivation and validation data sets
Derivation data set Validation data set
Cluster
Features
of cluster
K-S tests
Comments Cluster
Features
of cluster
K-S tests
CommentsK-S score P value K-S score P value
A Young, mild,
paucigranulocytic
a
Lower serum
periostin level
0.365 .003 More likely GINA
step 2 (P < .001)
Lower serum
periostin
level
0.758 .03 More likely
GINA step 2
(P 5 .001)
Predominantly
paucigranulocytic
sputum (P < .001)
Predominantly
paucigranu-
locytic
sputum
(P 5 .04)
Lowest median
ACQ7 score (1.6)
Lowest
median
ACQ7
score (0.8)
Youngest median
age (38 y)
Youngest
median age
(34 y)
B Older, sinonasal
disease
b
Higher serum
periostin level
0.746 .001 Oldest median
age (60 y)
Higher serum
periostin
level
0.709 <.001 Joint oldest
median age
(61 y)
Higher sputum
MMP3 level
0.610 .03 Highest median
HAD score (18)
Higher sputum
MMP3 level
0.562 .04 Highest median
HAD score
(27)
Higher SNOT-20
score
0.533 .04 Higher
SNOT-20
score
0.803 <.001
C Obese, high MMP
level
c
Higher sputum
MMP1 level
0.498 .02 Highest BMI (36.4) Higher sputum
MMP levels
0.735 .006 Highest BMI
(30.9) after
group i
Higher sputum
MMP8 level
0.481 .03
Higher sputum
MMP2 level
0.474 .03
Lower serum
periostin level
0.802 <.001 Lower serum
periostin level
0.746 .002
D This group was not
replicated in the
validation set
Higher serum
periostin level
0.780 .02
Higher HAD
Depression
score
0.695 .04
E Steroid resistant
TH2 mediated,
eosinophilic
e
Higher serum
periostin level
0.811 <.001 More likely
eosinophilic
sputum class
(P 5 .03)
Higher serum
periostin level
0.862 .002 Predominantly
(60%)
eosinophilic
sputum class
Higher
eosinophilia
0.524 .008 Higher
eosinophilia
0.981 .05
Higher sputum
IL-5 level
0.503 .01 Highest median FENO
value (33 ppb)
Higher sputum
IL-5 level
1.00 .04 Highest median
FENO value
(72 ppb)
(Continued)
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TABLE IV. (Continued)
Derivation data set Validation data set
Cluster
Features
of cluster
K-S tests
Comments Cluster
Features
of cluster
K-S tests
CommentsK-S score P value K-S score P value
Youngest median age
of onset (4 y)
Youngest
median age
of onset
(13 y)
F Mixed granulocytic
inflammation with
severe obstruction
f
Higher serum
periostin level
0.781 <.001 Higher serum
periostin level
0.569 <.001
Higher sputum
ECP level
0.503 .005 Higher sputum
ECP level
0.413 .04
Higher sputum
neutrophil
count
0.465 .003 Higher sputum
neutrophil
count
0.373 .04
Higher sputum
eosinophil
count
0.391 .0197 Higher sputum
eosinophil
count
0.438 .01
Higher HAD
Depression
score
0.367 .03 Higher HAD
Depression
score
0.379 .04
Lower FEV1
(% predicted,
pre-BD)
0.495 .001 Lower FEV1
(% predicted,
pre-BD)
0.379 .04
Lower FEV1/
FVC ratio
0.479 .002 Lower FEV1/
FVC ratio
0.463 .005
Lower sputum
macrophage
counts
0.409 .01 Lower sputum
macrophage
counts
0.438 .01
G This group was not
replicated in the
validation set
Higher
neutrophilia
0.304 .05
Higher sputum
osteopontin
level
0.300 .05
Higher blood
neutrophil
count
0.292 .02
Higher ACQ7
score
0.285 .02
Lower serum
periostin level
0.426 <.001
Lower sputum
MMP9 level
0.378 .006
Lower sputum
a2M level
0.350 .01
Lower sputum
FGF level
0.303 .05
Lower SF-36
score
0.344 .003
Lower AQLQ
score
0.289 .02
H Neutrophilic disease
with severe
obstruction, low
periostin level
(Continued)
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TABLE IV. (Continued)
Derivation data set Validation data set
Cluster
Features
of cluster
K-S tests
Comments Cluster
Features
of cluster
K-S tests
CommentsK-S score P value K-S score P value
Higher sputum
neutrophil
count
0.667 <.001 More likely
neutrophilic
sputum class
(P < .0001)
Higher sputum
neutrophil
count
0.639 .003 More likely
neutrophilic
sputum class
(P 5 .005)
Lower FEV1
(% predicted,
pre-BD)
0.569 <.001 Lower FEV1
(% predicted,
pre-BD)
0.490 .04
Lower FEV1
(% predicted,
post-BD)
0.562 <.001 Very low FEV1
(44% of predicted
value, pre-BD)
Lower FEV1
(% predicted,
post-BD)
0.519 .03 Lowest FEV1
(48% of
predicted
value,
pre-BD)
Lower periostin
level
0.495 <.001 Highest median
ACQ score (3.3)
Lower periostin
level
0.639 .003 High median
ACQ score
(3.4)
i This group was
not replicated
in the validation
set
Higher SNOT-20
score
0.677 .03
Higher sputum
macrophage
counts
0.631 .05
Lower AQLQ
emotional
score
0.677 .03
Lower periostin
level
0.646 .04
Features of clusters were identified in the training and validation sets by using TDA. Features are listed that differ significantly in the cluster when compared with all other subjects
in the same cohort.
a2M, a2-Macroglobulin; AQLQ, Juniper Asthma Quality of Life Questionnaire; BD, bronchodilator; BDP, beclomethasone dipropionate equivalent; BMI, body mass index;
FGF, fibroblast growth factor; FVC, forced vital capacity; GINA, Global Initiative for Asthma; MPO, myeloperoxidase; SNOT-20, Sino-Nasal Outcome Test 20.
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asthma.
Several previous studies have investigated the existence of
endotypes by using predominantly clinical parameters, which are
straightforward to apply.3,7,24 Other studies have incorporated the
additional dimension of sputum cell differential.5,6,8 Haldar et al6
observed 2 clusters characterized by discordance between
symptoms and eosinophilic inflammation. Likewise, Wu et al5
included peripheral blood counts and bronchoalveolar lavage
cell differentials when conducting a machine learning approach
to analyze Severe Asthma Research Programme (SARP) data,
identifying 6 asthma clusters. However, their analysis did not
include induced sputum, and the composition of the clusters
was again influenced mostly by clinical parameters because the
selected markers of eosinophilic or neutrophilic inflammation
provided only modest discriminating power in the model
(INFOGAIN value, 0.12-0.16). Our analyses included sputum
eosinophil and neutrophil counts; sputum subclass determination;
measurement of FENO, periostin, high-sensitivity C-reactive
protein, and serum IgE levels; and a restricted number of
clinical parameters found to be nonredundant and have strong
discriminatory power in our previous study.10 We identified 6
endotypes that could be replicated robustly in the validationcohort. The 2 dimensions of neutrophilic and eosinophilic
inflammation are strongly influential in defining the shape of
the data set and the composition of these clusters. As is clear
from the Bayesian analysis, airway neutrophilia and eosinophilia
represent 2 distinct inflammatory networks that likely contribute
separately to asthma symptoms, again underlining the importance
of considering these 2 specific dimensions when phenotyping an
individual patient.
It is interesting that we identified more than 1 eosinophilic or
neutrophilic cluster. Although airway eosinophilia and high
periostin levels were common to clusters E and F, cluster F had
the additional component of neutrophilic inflammation, leading
to higher symptom scores and a mixed granulocytic subtype.25
Sputum ECP levels were significantly increased in group F
(Table IV). ECP is a basic protein released during eosinophil
degranulation and is highly correlated in our Bayesian
analysis with both neutrophilic (sputum myeloperoxidase) and
eosinophilic (sputum eosinophils and IL-5) inflammation (Fig 3
and see Fig E11). In the derivation cohort an additional
neutrophilic cluster (ie, cluster G) was identified but not
replicated, likely because of the small sample size, perhaps
representing a milder spectrum of neutrophilic asthma with low
periostin levels.
FIG 2. Multidimensional clinicopathological clusters in asthmatic patients in the derivation data set
(Southampton cohort). A topological network generated by using 22 clinical and pathological features
together identifies 1 healthy (in blue) and 8 distinct clinicopathobiologic asthma clusters (A-H). The network
is colored according to ACQ7 scores, with themost symptomatic subjects in red. The TDA used 145 subjects
with the most complete data: metric, variance-normalized Euclidean; lenses, principal and secondary
singular value decomposition (resolution, 30; gain, 3.0/3.03, equalized) and presence/absence of asthma;
node size, proportional to the number of subjects in the node. Color bars: red, highest ACQ7 score; blue,
healthy participants. Features in boldface were replicated in the validation data set. GINA, Global Initiative
for Asthma.
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analogous clusters we previously described in a separate cohort10
suggest our analytic approach produces consistent findings and
that these clusters are likely related to fundamental differences
in underlying disease mechanisms. The previous study aimed to
investigate the full spectrum of clinical asthma. Thus 2 clusters
of moderate disease in the IL-17 cohort were not replicated in
the current study, which enrolled very few patients with moderate
asthma, focusing instead on severe asthma, which is typical of our
difficult asthma clinics.
How might our clusters relate to possible treatments? Our
description of group E is consistent with descriptions by Haldar
et al,6 Newby et al,8Wu et al,5 Fingleton et al,9 andHinks et al10 of
a cluster of highly atopic, early-onset, eosinophilic asthma with
high FENO values. We have shown this group to be characterized
by high serum periostin and sputum IL-5 levels (see Fig E4 and
Hinks et al10) despite high-dose corticosteroids, suggesting alikely response to agents, such as mepolizumab, targeting the
IL-5 pathway. That the type 2 cytokines IL-5 and IL-13 are not
associated in the Bayesian network and were not correlated in
sputum suggests IL-13 is more susceptible to steroid therapy.10
Conversely, like others,9 we found mean serum IgE levels to be
increased in all clusters, suggesting anti-IgE therapies might
benefit several phenotypes. As before,10 we found no evidence
of a significant dysregulation of airway IL-17 in any subgroup,
implying this cytokine might not be a promising target.
In contrast to recent developments of therapies targeting
TH2-mediated eosinophilic inflammation, there has been little
progress in therapeutics for neutrophilic disease. Our Bayesian
network highlights the prominent role of YKL-40 in neutrophilic
inflammation. YKL-40 is a chitinase-like protein expressed by
differentiated macrophages and is believed to regulate the magni-
tude of tissue injury and fibroproliferative repair in neutrophil
granules.26 YKL-40 polymorphisms are associated with asthma,
FIG 3. Bayesian belief network showing the strongest interactions between pathobiologic parameters
across a range of clinical severities of asthma or health. Nodes without strong interactions are excluded.
Line thickness represents the strength of the interaction (Euclidean distance). Line colors: green, positive
associations; red, negative associations; black, nonlinear associations. AQLQ, Juniper Asthma Quality of
Life Questionnaire; BD, bronchodilator; FGF, fibroblast growth factor; GCSF, Granulocyte-colony
stimulating factor; GINA, Global Initiative for Asthma; MPO, myeloperoxidase; SPT, skin prick test; VEGF,
vascular endothelial growth factor.
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Serum and sputum YKL-40 levels are increased in patients
with severe asthma and correlate with disease severity, airway
obstruction, and basement membrane thickness.29,30We observed
a very strong correlation between sputum YKL-40 and sputum
IL-8 levels, in addition to several other markers of neutrophilic
inflammation, which is consistent with ex vivo observations that
YKL-40 induces IL-8 from bronchial epithelia and stimulates
smooth muscle proliferation.31 In addition, airway YKL-40 level
increases in human allergen challenge and murine models impli-
cate YKL-40 in airway eosinophilia and IL-5 production.26 In our
data a moderate association (rs 5 0.477, P < .0001, data not
shown) was seen with sputum IL-5 levels. Although genetic and
in vitro data are suggestive, it remains to be determined whether
YKL-40 plays a causative role in asthma or is simply a marker
of extracellular tissue remodeling.
MMPs have also been implicated in tissue remodeling in
asthmatic patients by human genetic studies,32,33 murine emphy-
sema models,34-36 and the findings of increased bronchoalveolar
lavage MMP3 and MMP9 levels in patients with status asthmati-
cus37 and increased sputum MMP12 levels in asthmatic
smokers.38 Our study, the largest to date, confirms and extends
these findings with robust evidence of an increase in levels ofspecific MMPs in patients with severe asthma. These include
MMP1, MMP3, and MMP8, the 3 secreted type 3 collagenases
able to degrade collagen at neutral pH. We show that these are
strongly associated with neutrophilic inflammation, dysregulated
in obese asthmatic patients, and correlated positively with sputum
IL-5 levels but negatively with sputum IL-13 levels, perhaps
because MMP8 cleaves the IL-13 decoy receptor (IL-13 receptor
a2).20
In conclusion, we have identified and replicated 6 clinicopa-
thobiologic clusters using assays and sputum induction available
in clinical practice. Our data underline a disconnect between
clinical features and underlying inflammation, suggest IL-5
production is relatively steroid insensitive, and highlight the roles
of YKL-40 in neutrophilic inflammation and specific MMPs in
severe asthma.
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FIG 4. Inflammatory mediators associated with sputum YKL-40 levels. Spearman correlations between
levels of sputum YKL-40 and sputummyeloperoxidase (MPO;A), IL-8 (B), vascular endothelial growth factor
(VEGF; C), elastase (D), IL-6 soluble receptor (IL-6SR; E), IL-6 (F), neutrophils (G), and serum YKL-40 (H) are
shown.
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d We have identified and replicated 6 clinicopathobiologic
asthma endotypes.
d MMP1, MMP3, MMP8, and MMP12 levels are increased
in patients with severe asthma and associated with
sputum IL-5 levels.
d YKL-40 is strongly implicated in neutrophilic asthma.
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